| |
| |
|
| Insider
Information: |
Cox John |
| Relationship: |
|
| City: |
Weston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
44,968 |
|
|
Indirect Shares
|
4,444 |
|
|
| Direct
Value |
$8,932,433 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
49,412 |
|
|
| Total
Value |
$8,932,433 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 401.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biogen Idec Inc |
BIIB |
EVP Pharmaceutical Ope... |
2016-04-01 |
39,045 |
|
0 |
Premium* |
|
|
Repligen Corp |
RGEN |
Director |
2020-03-24 |
923 |
2015-05-21 |
0 |
Premium* |
|
|
Bioverativ Inc. |
BIVV |
Chief Executive Office... |
2018-03-08 |
0 |
2017-02-28 |
0 |
Premium* |
|
|
Sigilon Therapeutics, Inc. |
SGTX |
|
2023-08-11 |
0 |
2020-12-08 |
4,444 |
Premium* |
|
|
Dyne Therapeutics, Inc. |
DYN |
|
2024-03-25 |
5,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
85 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(185,094) |
0 |
0 |
- |
|
| SGTX |
Sigilon Therapeutics, Inc... |
|
– • – |
2023-08-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(341) |
0 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-24 |
4 |
S |
$96.72 |
$179,706 |
D/D |
(1,858) |
923 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2015-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
1,858 |
1,858 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-02-24 |
4 |
S |
$92.76 |
$413,455 |
D/D |
(4,455) |
2,781 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-04 |
4 |
S |
$93.39 |
$933,900 |
D/D |
(10,000) |
2,781 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-18 |
4 |
S |
$95.13 |
$2,547,035 |
D/D |
(26,736) |
2,781 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,763 |
3,621 |
0 |
- |
|
| SGTX |
Sigilon Therapeutics, Inc... |
Director |
– • – |
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
4,444 |
4,444 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2017-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,206 |
4,827 |
0 |
- |
|
| DYN |
Dyne Therapeutics, Inc. |
CEO & President |
• • – |
2024-03-25 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2018-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,486 |
6,313 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,236 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-05-03 |
4 |
D |
$97.99 |
$74,962 |
D/D |
(765) |
9,588 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-11-01 |
4 |
AS |
$114.37 |
$248,755 |
D/D |
(2,175) |
9,588 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-03-02 |
4 |
S |
$70.08 |
$283,259 |
D/D |
(4,041) |
9,818 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-03-31 |
4 |
AS |
$73.00 |
$207,320 |
D/D |
(2,840) |
9,818 |
0 |
- |
|
| DYN |
Dyne Therapeutics, Inc. |
See Remarks |
• • – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
% |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-04-11 |
4 |
AS |
$78.00 |
$538,200 |
D/D |
(6,900) |
10,353 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-04-13 |
4 |
AS |
$80.00 |
$2,898,720 |
D/D |
(36,234) |
10,353 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-04-21 |
4 |
AS |
$100.00 |
$435,000 |
D/D |
(4,350) |
10,353 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-11-01 |
4 |
OE |
$72.87 |
$158,492 |
D/D |
2,175 |
11,763 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2012-05-03 |
4 |
D |
$134.26 |
$102,709 |
D/D |
(765) |
12,178 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2011-03-31 |
4 |
OE |
$43.50 |
$123,540 |
D/D |
2,840 |
12,658 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• – – |
2012-02-24 |
4 |
D |
$116.39 |
$183,663 |
D/D |
(1,578) |
12,713 |
0 |
- |
|
85 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
